GE Healthcare and G-CON Collaborate to Develop "Vaccine Factory in a Box"
GE Healthcare (Uppsala, Sweden) and G-Con Manufacturing LLC (College Station, TX) will develop a modular portable bioprocess manufacturing solution for vaccines and therapeutics. This collaboration combines GE Healthcare?s global presence and expertise in biopharmaceutical manufacturing technology with G-Con?s modular portable cleanroom technology.
GE Healthcare (Uppsala, Sweden) and G-Con Manufacturing LLC (College Station, TX) will develop a modular portable bioprocess manufacturing solution for vaccines and therapeutics. This collaboration combines GE Healthcare’s global presence and expertise in biopharmaceutical manufacturing technology with G-Con’s modular portable cleanroom technology.
According to the press release, the collaboration will offer GMP manufacturing solutions that are less expensive and quicker to build and maintain and easier to operate. The aim of this collaboration is to meet the growing market for rapid access to biopharmaceutical manufacturing capabilities, whether in developing markets, or for increased speed in situations such as pandemic response.
“This collaboration means we move further towards our vision of modular and possibly mobile flexible bio-pharmaceutical manufacturing facilities—the vaccine factory in a box,” said Nigel Darby, vice president of biotechnologies, GE Healthcare.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
